Clinical trial shows gene editing works for β-Thalassaemia, too Improved gene editing process reactivates the fetal version of a hemoglobin gene.

📢 Classic! Just as I thought 😏 A recent Phase II trial using CRISPR/Cas9 edited 80% of beta‑globin genes in patients, showing lasting relief from β‑thalassaemia. This breakthrough could redefine future therapies. Will 100% gene correction soon? #geneediting #thalasemia #CRISPR